[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100431655":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":30,"locations":35,"responsibleParty":54,"collaborators":57,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":18,"eligibilityCriteria":66,"healthyVolunteers":63,"sex":67,"minAge":68,"maxAge":18,"enrollmentInfo":69,"targetDuration":18,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":85,"overallStatus":37,"whyStopped":18,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"POISE","EXPERIMENTAL","The intervention will be a structured palliative care intervention in which patients will meet with a palliative care clinician who has been trained on a manual with specific topics to be covered in each of the four visits:\n\n* Three surveys: baseline, 12-week, and 20-week post-enrollment\n* Four 60-minute visits with a trained palliative care clinician\n* Semi-structured exit interview\n* Chart review",[13],"Behavioral: POISE",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual care","NO_INTERVENTION","Patients randomized to usual care will receive usual oncology care. They may access standard palliative care as clinically indicated.",null,[20],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"BEHAVIORAL","POISE (Patient-centered, Optimal Integration of Survivorship and palliative carE) is a brief, population-specific intervention that consists of four sessions with palliative care specialists who have been additionally trained to evaluate and address the specific psychosocial issues and health-promoting behaviors of patients with long, uncertain cancer trajectories.",[9],[25],"palliative care intervention",[27],{"name":28,"affiliation":5,"role":29},"Laura A Petrillo, MD","PRINCIPAL_INVESTIGATOR",[31],{"name":28,"role":32,"phone":33,"phoneExt":18,"email":34},"CONTACT","(617) 724-4000","lpetrillo2@mgh.harvard.edu",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Boston","Massachusetts","02115","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-71.05977,42.35843,{"lat":47,"lon":46},[50,53],{"name":51,"role":32,"phone":52,"phoneExt":18,"email":34},"Laura A. Petrillo, MD","617-724-4000",{"name":51,"role":29,"phone":18,"phoneExt":18,"email":18},{"type":29,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Laura Petrillo, M.D.","Principal Investigator",[58],{"name":59,"class":60},"National Cancer Institute (NCI)","NIH","100431655","patient-centered-optimal-integration-of-survivorship-and-palliative-care-100431655",false,"NCT04900935","Patient-centered, Optimal Integration of Survivorship and Palliative Care","Inclusion Criteria:\n\n* Age 18 or older\n* MGH Cancer Center patient\n* Within 6 months of diagnosis of metastatic NSCLC with oncogenic driver mutation (EGFR, ALK, ROS1, RET)\n* Receiving targeted therapy\n* Ability to respond in English or Spanish\n\nExclusion Criteria:\n\n* Cognitive impairment or serious mental illness that limits ability to provide informed consent\n* Need for urgent palliative care or hospice referral\n* Pregnant women\n* Prisoners","ALL","18 Years",{"count":70,"type":71},70,"ESTIMATED","INTERVENTIONAL",[74],"NA","The goal of this study is to develop and test the feasibility of a supportive care model (POISE) for patients with metastatic Non-small Cell Lung Cancer (NSCLC). The main questions are\n\n* is POISE feasible to deliver and acceptable to patients\n* what is the effect of POISE on the distress patients feel related to their uncertain future, their confidence in their ability to manage cancer, and their understanding about what to expect Participants in the randomized controlled trial will receive either the new supportive care model, POISE, which consists of four visits with a trained palliative care clinician, or care as usual, and will be asked to complete three surveys.",[77,78,79,80,81,82,83,84],"Stage IV Non-small Cell Lung Cancer","Targeted Therapy","Nonsmall Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung","ALK-positive Non-small Cell Lung Cancer","EGFR Positive Non-small Cell Lung Cancer","Palliative Care","Survivorship",[77,78,79,80,81,82,86,87,88,89],"ROS1 Positive Non-Small Cell Lung Cancer","Palliative care","survivorship","RET Fusion positive Non-Small Cell Lung Cancer","2025-11-19",{"date":92,"type":93},"2025-11-24","ACTUAL",{"date":95,"type":93},"2023-09-29",{"date":97,"type":71},"2027-09-01",{"name":5,"class":6},1]